SCHEMBL6033002

SCHEMBL6033002

CC1(C)CCC(C)(C)c2c(OCc3ccccc3)cc([Se]c3ccc(C(=O)O)cc3)cc21

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RXRA P19793 11/20 0.44
RXRB P28702 6/20 0.44
RXRG P48443 5/20 0.44
HNF4A P41235 3/20 0.44
NR4A1 P22736 1/20 0.43
NR4A2 P43354 1/20 0.43
NR4A3 Q92570 1/20 0.43
CYP26A1 O43174 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP26B1 Q9NR63 1/20 0.42
MRGPRX4 Q96LA9 2/20 0.42
RARB P10826 2/20 0.42
RARG P13631 2/20 0.42
RARA P10276 1/20 0.42
SRD5A2 P31213 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6032919 0.87 MRGPRX4 (0.48) RXRANR4A2MRGPRX4HPGD
SCHEMBL6033247 0.87 GCK (0.42) RXRARXRBRXRGHNF4ACYP26A1
SCHEMBL6032620 0.79 L3MBTL1 (0.41) MRGPRX4
SCHEMBL4942429 0.79 RARB (0.43) RXRARXRBRXRGHNF4ACYP26A1
SCHEMBL4948642 0.79 RARB (0.41) RXRARXRBRXRGNR4A1NR4A2
SCHEMBL4948843 0.79 RARB (0.44) RXRARXRBRXRGHNF4ACYP26A1
SCHEMBL4951005 0.79 NR4A2 (0.49) RXRAHNF4ANR4A2CYP26A1CYP3A4
SCHEMBL4943814 0.78 NR4A2 (0.44) RXRARXRBRXRGHNF4ANR4A2
SCHEMBL4947926 0.78 NR4A2 (0.44) RXRARXRBRXRGHNF4ANR4A2
SCHEMBL4943199 0.78 RXRA (0.44) RXRARXRBRXRGHNF4ACYP26A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060014803-A1 Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2006-01-19 US claimed
EP-1086080-B1 DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2004-08-25 EP claimed
US-6992094-B1 Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2006-01-31 US disclosed
US-20060014803-A1 Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014803-A1 Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics TYR, DERL1, GPX1 RXRA 1865/4885RXRB 1881/4885RXRG 1599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.